Contemporary approach to diagnosis and treatment of neuroblastoma.
Identifieur interne : 000822 ( Main/Exploration ); précédent : 000821; suivant : 000823Contemporary approach to diagnosis and treatment of neuroblastoma.
Auteurs : RBID : pubmed:23474634English descriptors
- KwdEn :
- 3-Iodobenzylguanidine (diagnostic use), 3-Iodobenzylguanidine (therapeutic use), Animals, Bone and Bones (radionuclide imaging), Central Nervous System Neoplasms (radionuclide imaging), Central Nervous System Neoplasms (therapy), Child, Child, Preschool, Clinical Trials as Topic, Diagnostic Imaging (methods), Disease Models, Animal, Female, Humans, Infant, Kinetics, Male, Medical Oncology (methods), Mice, Neuroblastoma (diagnosis), Neuroblastoma (therapy), Octreotide (analogs & derivatives), Octreotide (diagnostic use), Patient Safety, Radiometry (methods), Radionuclide Imaging (methods), Radiopharmaceuticals (diagnostic use), Radiopharmaceuticals (therapeutic use), Recurrence, Remission Induction, Sensitivity and Specificity, Tissue Distribution.
- MESH :
- chemical , analogs & derivatives : Octreotide.
- chemical , diagnostic use : 3-Iodobenzylguanidine, Octreotide, Radiopharmaceuticals.
- chemical , therapeutic use : 3-Iodobenzylguanidine, Radiopharmaceuticals.
- diagnosis : Neuroblastoma.
- methods : Diagnostic Imaging, Medical Oncology, Radiometry, Radionuclide Imaging.
- radionuclide imaging : Bone and Bones, Central Nervous System Neoplasms.
- therapy : Central Nervous System Neoplasms, Neuroblastoma.
- Animals, Child, Child, Preschool, Clinical Trials as Topic, Disease Models, Animal, Female, Humans, Infant, Kinetics, Male, Mice, Patient Safety, Recurrence, Remission Induction, Sensitivity and Specificity, Tissue Distribution.
Abstract
The diagnostic value of Metaiodobenzylguanidine (MIBG) scintigraphy in the management of neuroblastoma is well established. The specificity of MIBG is virtually 100% and remains the most specific imaging modality. Numerous semi-quantitative scores and guidelines have emerged in the last decade that illustrate standardization of the procedure. Other pharmaceuticals such as norcholesterol derivatives, [111In]pentetreotide and [68Ga]somatostatin analogs, [18F]fluorodeoxyglucose, [18F]fluorodopa, [18F]fluorodopamine, [11C]meta hydroxyephedrine, and [11C] /[18F] /[123I]Metomidate (MTO) have been or are being evaluated currently (including development of new analogues labeled with positron emitting radionuclides such as [124I], [18F], and [76Br]. Radiopharmaceutical therapy of neuroblastoma, initiated over 30 years ago, demonstrates that a significant fraction of patients enter partial remission but complete remission is rare and relapse is frequent. With the combination of chemotherapy, radiosensitizers, and autologous stem cell support, some centers have seen overall response rates of up to 30% in refractory or recurrent diseases. Topoisomerase I inhibitor topotecan may improve upon existing [131I]MIBG therapy. Areas of future development may be in vitro cultures and animal models, proper instrumentation to acquire sub-centimeter resolution and human clinical trials to evaluate treatment at earlier times or stages of disease, evaluation with concomitant immunotherapy with monoclonal antibodies targeting the GD2 ganglioside or inhibitors of anaplastic lymphoma kinase. Because of the complexity of those trials, progress remains extremely slow as well designed multicenter studies are required. Nonetheless, the future has never been so hopeful.
PubMed: 23474634
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Contemporary approach to diagnosis and treatment of neuroblastoma.</title><author><name sortKey="Charron, M" uniqKey="Charron M">M Charron</name><affiliation wicri:level="1"><nlm:affiliation>Department of Diagnostic Imaging, University of Toronto, Canada. martin.charron@sickkids.ca</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Diagnostic Imaging, University of Toronto</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><date when="2013">2013</date><idno type="RBID">pubmed:23474634</idno><idno type="pmid">23474634</idno><idno type="wicri:Area/Main/Corpus">000754</idno><idno type="wicri:Area/Main/Curation">000754</idno><idno type="wicri:Area/Main/Exploration">000822</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>3-Iodobenzylguanidine (diagnostic use)</term><term>3-Iodobenzylguanidine (therapeutic use)</term><term>Animals</term><term>Bone and Bones (radionuclide imaging)</term><term>Central Nervous System Neoplasms (radionuclide imaging)</term><term>Central Nervous System Neoplasms (therapy)</term><term>Child</term><term>Child, Preschool</term><term>Clinical Trials as Topic</term><term>Diagnostic Imaging (methods)</term><term>Disease Models, Animal</term><term>Female</term><term>Humans</term><term>Infant</term><term>Kinetics</term><term>Male</term><term>Medical Oncology (methods)</term><term>Mice</term><term>Neuroblastoma (diagnosis)</term><term>Neuroblastoma (therapy)</term><term>Octreotide (analogs & derivatives)</term><term>Octreotide (diagnostic use)</term><term>Patient Safety</term><term>Radiometry (methods)</term><term>Radionuclide Imaging (methods)</term><term>Radiopharmaceuticals (diagnostic use)</term><term>Radiopharmaceuticals (therapeutic use)</term><term>Recurrence</term><term>Remission Induction</term><term>Sensitivity and Specificity</term><term>Tissue Distribution</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Octreotide</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>3-Iodobenzylguanidine</term><term>Octreotide</term><term>Radiopharmaceuticals</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>3-Iodobenzylguanidine</term><term>Radiopharmaceuticals</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Neuroblastoma</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Diagnostic Imaging</term><term>Medical Oncology</term><term>Radiometry</term><term>Radionuclide Imaging</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Bone and Bones</term><term>Central Nervous System Neoplasms</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Central Nervous System Neoplasms</term><term>Neuroblastoma</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Child</term><term>Child, Preschool</term><term>Clinical Trials as Topic</term><term>Disease Models, Animal</term><term>Female</term><term>Humans</term><term>Infant</term><term>Kinetics</term><term>Male</term><term>Mice</term><term>Patient Safety</term><term>Recurrence</term><term>Remission Induction</term><term>Sensitivity and Specificity</term><term>Tissue Distribution</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The diagnostic value of Metaiodobenzylguanidine (MIBG) scintigraphy in the management of neuroblastoma is well established. The specificity of MIBG is virtually 100% and remains the most specific imaging modality. Numerous semi-quantitative scores and guidelines have emerged in the last decade that illustrate standardization of the procedure. Other pharmaceuticals such as norcholesterol derivatives, [111In]pentetreotide and [68Ga]somatostatin analogs, [18F]fluorodeoxyglucose, [18F]fluorodopa, [18F]fluorodopamine, [11C]meta hydroxyephedrine, and [11C] /[18F] /[123I]Metomidate (MTO) have been or are being evaluated currently (including development of new analogues labeled with positron emitting radionuclides such as [124I], [18F], and [76Br]. Radiopharmaceutical therapy of neuroblastoma, initiated over 30 years ago, demonstrates that a significant fraction of patients enter partial remission but complete remission is rare and relapse is frequent. With the combination of chemotherapy, radiosensitizers, and autologous stem cell support, some centers have seen overall response rates of up to 30% in refractory or recurrent diseases. Topoisomerase I inhibitor topotecan may improve upon existing [131I]MIBG therapy. Areas of future development may be in vitro cultures and animal models, proper instrumentation to acquire sub-centimeter resolution and human clinical trials to evaluate treatment at earlier times or stages of disease, evaluation with concomitant immunotherapy with monoclonal antibodies targeting the GD2 ganglioside or inhibitors of anaplastic lymphoma kinase. Because of the complexity of those trials, progress remains extremely slow as well designed multicenter studies are required. Nonetheless, the future has never been so hopeful.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">23474634</PMID><DateCreated><Year>2013</Year><Month>03</Month><Day>11</Day></DateCreated><DateCompleted><Year>2013</Year><Month>06</Month><Day>17</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1824-4785</ISSN><JournalIssue CitedMedium="Print"><Volume>57</Volume><Issue>1</Issue><PubDate><Year>2013</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology</Title><ISOAbbreviation>Q J Nucl Med Mol Imaging</ISOAbbreviation></Journal><ArticleTitle>Contemporary approach to diagnosis and treatment of neuroblastoma.</ArticleTitle><Pagination><MedlinePgn>40-52</MedlinePgn></Pagination><Abstract><AbstractText>The diagnostic value of Metaiodobenzylguanidine (MIBG) scintigraphy in the management of neuroblastoma is well established. The specificity of MIBG is virtually 100% and remains the most specific imaging modality. Numerous semi-quantitative scores and guidelines have emerged in the last decade that illustrate standardization of the procedure. Other pharmaceuticals such as norcholesterol derivatives, [111In]pentetreotide and [68Ga]somatostatin analogs, [18F]fluorodeoxyglucose, [18F]fluorodopa, [18F]fluorodopamine, [11C]meta hydroxyephedrine, and [11C] /[18F] /[123I]Metomidate (MTO) have been or are being evaluated currently (including development of new analogues labeled with positron emitting radionuclides such as [124I], [18F], and [76Br]. Radiopharmaceutical therapy of neuroblastoma, initiated over 30 years ago, demonstrates that a significant fraction of patients enter partial remission but complete remission is rare and relapse is frequent. With the combination of chemotherapy, radiosensitizers, and autologous stem cell support, some centers have seen overall response rates of up to 30% in refractory or recurrent diseases. Topoisomerase I inhibitor topotecan may improve upon existing [131I]MIBG therapy. Areas of future development may be in vitro cultures and animal models, proper instrumentation to acquire sub-centimeter resolution and human clinical trials to evaluate treatment at earlier times or stages of disease, evaluation with concomitant immunotherapy with monoclonal antibodies targeting the GD2 ganglioside or inhibitors of anaplastic lymphoma kinase. Because of the complexity of those trials, progress remains extremely slow as well designed multicenter studies are required. Nonetheless, the future has never been so hopeful.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Charron</LastName><ForeName>M</ForeName><Initials>M</Initials><Affiliation>Department of Diagnostic Imaging, University of Toronto, Canada. martin.charron@sickkids.ca</Affiliation></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Journal Article</PublicationType><PublicationType>Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Q J Nucl Med Mol Imaging</MedlineTA><NlmUniqueID>101213861</NlmUniqueID><ISSNLinking>1824-4785</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>indium-111-octreotide</NameOfSubstance></Chemical><Chemical><RegistryNumber>35MRW7B4AD</RegistryNumber><NameOfSubstance>3-Iodobenzylguanidine</NameOfSubstance></Chemical><Chemical><RegistryNumber>RWM8CCW8GP</RegistryNumber><NameOfSubstance>Octreotide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">3-Iodobenzylguanidine</DescriptorName><QualifierName MajorTopicYN="Y">diagnostic use</QualifierName><QualifierName MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Bone and Bones</DescriptorName><QualifierName MajorTopicYN="N">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Central Nervous System Neoplasms</DescriptorName><QualifierName MajorTopicYN="N">radionuclide imaging</QualifierName><QualifierName MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Diagnostic Imaging</DescriptorName><QualifierName MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Medical Oncology</DescriptorName><QualifierName MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Neuroblastoma</DescriptorName><QualifierName MajorTopicYN="Y">diagnosis</QualifierName><QualifierName MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Octreotide</DescriptorName><QualifierName MajorTopicYN="N">analogs & derivatives</QualifierName><QualifierName MajorTopicYN="N">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Patient Safety</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radiometry</DescriptorName><QualifierName MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radionuclide Imaging</DescriptorName><QualifierName MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radiopharmaceuticals</DescriptorName><QualifierName MajorTopicYN="N">diagnostic use</QualifierName><QualifierName MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Remission Induction</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Tissue Distribution</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pii">R39132583</ArticleId><ArticleId IdType="pubmed">23474634</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000822 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000822 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:23474634
|texte= Contemporary approach to diagnosis and treatment of neuroblastoma.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:23474634" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |